Symbol: CSTL

Current USD Price: $0.00074581551784

Market Cap: $16,367

24 Hour Change: -7.99012874%

1 Hour Change: 0.30909302%

Back Home

Top 25 Currencies

Name Price 1H Change
GlobalBoost-Y $0.0557053030844 0.31800759%
RigoBlock $0.739496395021 2.74733798%
Wings $0.0998035591184 1.31723555%
Smart MFG $0.0331078532411 2.47259054%
Noah Coin $7.580681433E-5 0.78688112%
AnimalGo $0.0103217862099 -1.65733056%
Super Zero Protocol $0.315202971768 1.1164871%
Dusk Network $0.26896669946 -0.38968947%
BlueCoin $0.00172111273348 0.30909302%
FC Barcelona Fan Token $33.4922796569 -0.1932426%
APIX $0.0818950332575 -0.18694332%
Clash Token $0.664837577712 2.74733798%
Yield Stake Finance $8.88542334608 -0.13892486%
Wrapped Bitcoin $57753.3455159 1.09897452%
Atlas Protocol $0.00382923587967 3.0693634%
Privatix $0.0894978621827 -8.48995022%
DSLA Protocol $0.015280141375 1.38793228%
DFI.Money $2552.35444231 1.0029369%
Mettalex $8.7604480559 -0.86932316%
CWV Chain $0.00277780757175 0.09529617%
Infinitus Token $0.151086268391 0%
HyperQuant $0.00098047954229 1.06302524%
PLNcoin $0.00057370424449 0.30909302%
Garlicoin $0.154390788455 -0.33789596%
Venus USDC $0.0204575451804 -0.02655441%

Major Gainers In The Last Hour

Name Price 1H Change
AIDUS TOKEN $0.0129043805827 91.28785028%
The ChampCoin $0.00429838776657 9.97746343%
Satozhi $1.69363584191 9.77549469%
UniLayer $2.43155356045 9.7547406%
Coinsuper Ecosystem Network $0.00156123304734 9.65081652%

Major Gainers In The Last 24 Hour

Name Price 24H Change
Dopple Finance $1.65326337069 99.43744484%
wave edu coin $0.00114827718378 98.81961922%
Ixinium $0.354711102427 98.7884039%
Sad Cat Token $7.486938316E-5 98.37123091%
onLEXpa $0.0001147408489 98.17510733%

Latest Castle News

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Do Analysts Expect Castle Biosciences Inc (CSTL) Stock to Rise After It Is Lower By -17.77% in a Month? - InvestorsObserver
Does This Valuation Of Castle Biosciences, Inc. (NASDAQ:CSTL) Imply Investors Are Overpaying? - Nasdaq
Should You Buy Castle Biosciences Inc (CSTL) Stock on Friday? - InvestorsObserver
Castle Biosciences Inc to Host Earnings Call - Yahoo Finance
Castle Biosciences: Q1 Earnings Insights - Benzinga
Castle Biosciences Announces First Quarter 2021 Results - Business Wire
Castle Biosciences Inc. (CSTL) to Acquire Myriad myPath Laboratory -
$CSTL Castle Biosciences Posts Q1 Loss Per Share Of 17 Cents - CML News
Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021 - Business Wire
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S. - Business Wire
Castle fortifies position in skin cancer detection with $32.5M Myriad Mypath acquisition - BioWorld Online
Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population - Business Wire
Castle Biosciences (NASDAQ:CSTL) Now Covered by Analysts at Lake Street Capital - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 14,374 Shares - MarketBeat
Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma - Yahoo Finance
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress - BioSpace
New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test - Business Wire
Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!?" Steps Challenge for Skin Cancer Awareness Month - Business Wire
Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy - Business Wire
Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma - Yahoo Finance
Castle Biosciences Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Pembroke Management, LTD Buys Chart Industries Inc, Danimer Scientific Inc, Castle Biosciences -
Castle Biosciences Shows Rising Relative Strength; Still Shy Of Key Threshold - Investor's Business Daily
Robert W. Baird Stick to Their Buy Rating for Castle Biosciences Inc By -
Today's Stock Market News & Events: 5/10/2021 - Schaeffers Research - Schaeffers Research
Is a Surprise Coming for Castle Biosciences (CSTL) This Earnings Season? - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Moves 5.3% Higher: Will This Strength Last? - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
How The Pieces Add Up: XHS Headed For $118 - Nasdaq
Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock - Business Wire
An Intrinsic Calculation For Castle Biosciences, Inc. (NASDAQ:CSTL) Suggests It's 41% Undervalued - Yahoo Finance
Here's What Analysts Are Forecasting For Castle Biosciences, Inc. (NASDAQ:CSTL) After Its Yearly Results - Nasdaq
Can Castle Biosciences Stock Rebound After The Recent 24% Drop? - Forbes
Have Insiders Been Selling Castle Biosciences, Inc. (NASDAQ:CSTL) Shares This Year? - Simply Wall St
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings - Benzinga
Is Castle Biosciences, Inc. (NASDAQ:CSTL) Popular Amongst Insiders? - Simply Wall St
Is it Time to Dump Castle Biosciences Inc (CSTL) Stock After it Has Gained 9.33% in a Week? - InvestorsObserver
Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock - Business Wire
Castle Biosciences Announces Early Repayment of Debt - Business Wire
Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire
Castle Biosciences Sinks 6% On Wider-Than-Expected 4Q Loss, Sales Top Estimates - Yahoo Finance
Bernhard Spiess Is The Chief Business Officer of Castle Biosciences, Inc. (NASDAQ:CSTL) And They Just Sold 77% Of Their Shares - Nasdaq
Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium - Business Wire
Should You Buy Castle Biosciences Inc (CSTL) in Diagnostics & Research Industry? - InvestorsObserver
Is CSTL A Good Stock To Buy Now? - Yahoo Finance
Earnings Scheduled For May 10, 2021 Companies Reporting Before The Bell ? Revlon - Benzinga
Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma - Business Wire
Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx?-Melanoma at 18th Annual Winter Clinical Dermatology Conference - Business Wire
Castle Biosciences Announces Third Quarter 2020 Results - Business Wire
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells 15,000 Shares of Stock - MarketBeat
US$60.00 - That's What Analysts Think Castle Biosciences, Inc. (NASDAQ:CSTL) Is Worth After These Results - Simply Wall St
Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions - Business Wire
Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma - Business Wire
(4/30/2021) CSTL Stock Has 60% Chance Of A Rise Over The Next Month After Rising 5.2% In The Last 5 Days. One-Month Expected Return For The Stock Is 4.3% - Trefis
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx® DiffDx?-Melanoma Tests at American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting - Business Wire
Post-IPO Review: Castle Biosciences Grows Despite Pandemic's Effects - TheStreet
Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx?-Melanoma for Suspicious Pigmented Lesions - Business Wire
Castle Biosciences Announces First Quarter 2020 Results - Business Wire
Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma - BioSpace
Castle Could Crumble When IPO Lockup Expires - Seeking Alpha
Castle Biosciences to Hold Web -
CSTL Price Target, Analyst Ratings and Predictions (Castle Biosciences) - MarketBeat
Inside ARK Innovation's Big Stakes in Small Companies -
How Will the Market React to Castle Biosciences Inc (CSTL) Stock Getting a Bearish Rating - InvestorsObserver
Castle Biosciences Announces Pricing of Initial Public Offering - Business Wire
Reasons Behind The 40% Jump In Castle BioSciences' Stock Since Early November - Trefis
James Glassman?s 10 Stock Market Picks for 2021 - Kiplinger's Personal Finance
James Glassman?s 10 Stock Market Picks for 2021  Kiplinger's Personal Finance
Castle Biosciences Appoints Miles Harrison to Board of Directors - Business Wire
Dow Jones Today, Stocks Slip Ahead Of Fed; Merger News Spikes Tilray; Twitter Aces Breakout - Investor's Business Daily
Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma - BioSpace
Castle Biosciences to hire, double Valley space after IPO - Phoenix Business Journal - Phoenix Business Journal
Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 35c, Revenues Beat November 11, 2019 4:06 -
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs - Benzinga
Castle Biosciences IPO: The Buying Opportunity Starts At 3x-3.5x Sales - Seeking Alpha
Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards? - Nasdaq
Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology - BioSpace
Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis - Business Wire
Castle Biosciences Added to NASDAQ Biotechnology Index - Business Wire
10 Biggest Price Target Changes For Friday - Benzinga
Study Results Confirm Newly Developed Nomogram Using Castle Biosciences' DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk - BioSpace
The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut - Benzinga
Editas Medicine -2.3% AH, announces stock offering - Seeking Alpha
Illumina upgraded at Canaccord Genuity with readthrough to other firms on FTC challenge - Seeking Alpha
The Daily Biotech Pulse: Roche & Moderna Strike COVID Testing Partnership, Rocket Pharma's Gene Therapy Readout, Breast Cancer Presentations - Benzinga
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding - Benzinga
What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings? - Nasdaq
Cathie Wood Risks Having Too Much Money and Not Enough Stocks - Bloomberg
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement - Benzinga
Bionano (BNGO) to Report Q4 Earnings: What's in the Offing? - Nasdaq
Castle Bio Eyes up to $61.3M in Planned IPO - GenomeWeb
Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic - BioSpace
Why Cryptocurrency Stocks Are Soaring Today - Nasdaq
The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment - Benzinga
Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards? -
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street - Benzinga
Invest Like a Rockefeller With These 'No Contest' Companies - DailyWealth